Payment overview · 2025
General Payments
$184.74
10 reported records · 7 companies
Healthcare provider profile · identity verified
Luvkarnjit Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · LEVITTOWN, PA · NPI 1063795284
Verified facts
What the public records show
CMS Open Payments records show Luvkarnjit Singh, M.D. received $184.74 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 19.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Lokelma by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $36.30 | 19.6% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.06 | 19.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.61 | 18.2% | 2 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $23.65 | 12.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.64 | 12.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $16.75 | 9.1% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $15.73 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $184.74 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $36.30 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $35.06 | 2 | 2025 |
Source payment records
|
|||||
| ONPATTRO Normalized: onpattro |
Drug | Alnylam Pharmaceuticals Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $23.64 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.03 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
260 | 43 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 577 | 128 |
| Levothyroxine Sodium | Levothyroxine Sodium | 310 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 79 |
| Gabapentin | Gabapentin | 289 | 59 |
| Eliquis | Apixaban | 260 | 43 |
| Furosemide | Furosemide | 250 | 52 |
| Lisinopril | Lisinopril | 211 | 49 |
| Mirtazapine | Mirtazapine | 211 | 37 |
| Sertraline Hcl | Sertraline Hcl | 201 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 53 |
| Metformin Hcl | Metformin Hcl | 178 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 176 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 171 | 21 |
| Trazodone Hcl | Trazodone Hcl | 168 | 46 |
| Potassium Chloride | Potassium Chloride | 167 | 35 |
| Buspirone Hcl | Buspirone Hcl | 135 | 34 |
| Xarelto | Rivaroxaban | 133 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 131 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 131 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 126 | 23 |
| Losartan Potassium | Losartan Potassium | 125 | 35 |
| Carvedilol | Carvedilol | 123 | 25 |
| Omeprazole | Omeprazole | 123 | 27 |
| Donepezil Hcl | Donepezil Hcl | 118 | 21 |
| Famotidine | Famotidine | 103 | 25 |
| Divalproex Sodium | Divalproex Sodium | 100 | 24 |
| Levetiracetam | Levetiracetam | 94 | 20 |
| Latanoprost | Latanoprost | 74 | 15 |
| Simvastatin | Simvastatin | 70 | 17 |
| Memantine Hcl | Memantine Hcl | 66 | 11 |
| Januvia | Sitagliptin Phosphate | 60 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 17 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 57 | 11 |
| Tramadol Hcl | Tramadol Hcl | 57 | 20 |
| Bumetanide | Bumetanide | 56 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 56 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 56 | 20 |
| Risperidone | Risperidone | 56 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 54 | 13 |
| Olanzapine | Olanzapine | 54 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 13 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 52 | suppressed |
| Jardiance | Empagliflozin | 52 | 12 |
| Lorazepam | Lorazepam | 50 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 12 |
| Aripiprazole | Aripiprazole | 46 | 12 |
| Clonazepam | Clonazepam | 42 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 40 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 38 | 16 |
| Glipizide | Glipizide | 37 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Ezetimibe | Ezetimibe | 36 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 36 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Budesonide | Budesonide | 32 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 32 | suppressed |
| Prednisone | Prednisone | 32 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 31 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Gemtesa | Vibegron | 30 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 29 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Digoxin | Digoxin | 27 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 26 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Nystatin | Nystatin | 25 | 13 |
| Levofloxacin | Levofloxacin | 24 | 16 |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Lacosamide | Lacosamide | 20 | suppressed |
| Verapamil Sr | Verapamil Hcl | 20 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | suppressed |
| Spironolactone | Spironolactone | 19 | 12 |
| Trulicity | Dulaglutide | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 16 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 15 | 13 |
| Cephalexin | Cephalexin | 15 | 12 |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Allopurinol | Allopurinol | 13 | suppressed |
| Asenapine Maleate | Asenapine Maleate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Invokana | Canagliflozin | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 12 | suppressed |
| Admelog Solostar | Insulin Lispro | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Meloxicam | Meloxicam | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $184.74 · 10 records | ABBVIE INC. | AIRSUPRA, MOUNJARO, NUPLAZID, ONPATTRO, OPSUMIT, UPTRAVI, VRAYLAR, VYNDAQEL, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error